The PlA1/A2 Polymorphism of Platelet Glycoprotein IIIa Is not Associated with Peripheral Arterial Disease

Wilfried Renner; Marianne Brodmann; Monika Winkler; Thomas C. Wascher; Ernst Pilger

doi:10.1055/s-0037-1615664

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2001; 85(04): 745-746
DOI: 10.1055/s-0037-1615664

Letters to the Editor

Schattauer GmbH

The PlA1/A2 Polymorphism of Platelet Glycoprotein IIIa Is not Associated with Peripheral Arterial Disease

Wilfried Renner

¹Division of Angiology

,

Marianne Brodmann

¹Division of Angiology

,

Monika Winkler

¹Division of Angiology

,

Thomas C. Wascher

²Diabetic Angiopathy Research Group, Department of Medicine, Unniversitätsklinikum Graz, Austria

,

Ernst Pilger

¹Division of Angiology

› Author Affiliations

Abstract

Full Text

References

References
1 Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotin IIIa, and are distinguishable by DNA typing. J Clin Invest 1989; 83: 1778-81.
2 Goodall AH, Curzen N, Panesar M, Hurd C, Knight CJ, Ouwehand WH, Fox KM. Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, PlA2, Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J 1999; 20: 742-7.
3 Bennet JS, Vilaire G, Catella-Lawson F, Rut AR, Fitzgerald GA. The PLA2 alloantigen does not alter the affinity of GP IIb-IIIa for fibrinogen or RGD-containing peptides (abstract). Blood 90: 154a.
4 Meiklejohn DJ, Urbaniak SJ, Greaves M. Platelet glycoprotein IIIa polymorphism HPA 1b (PlA2): no association with platelet fibrinogen binding. Br J Haematol 1999; 105: 664-6.
5 Feng D, Lindpaintner K, Larson MG, Rao VS, O’Donnell CJ, Lipinska I, Schmitz C, Sutherland PA, Silbershatz H, D’Agostino RB, Muller JE, Myers RH, Levy D, Tofler GH. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. ArteriosclerThromb Vasc Biol 1999; 19: 1142-7.
6 Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hen-drix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF. Platelet GP, III a Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101: 1013-8.
7 Lasne D, Krenn M, Pingault V, Arnaud E, Fiessinger JN, Aiach M, Rendu F. Interdonor variability of platelet response to thrombin receptor activation: influence of PlA2 polymorphism. Br J Haematol 1997; 99: 801-7.
8 Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmid-Clermont PJ. PLA2 polymorphism and efficacy of aspirin. Lancet 1998; 351: 1253.
9 Byzova TV, Plow EF. The Pl(A2) allele and cardiovascular disease: the pro(33) and con [comment]. J Clin Invest 2000; 105: 697-8.
10 Sanchez LA, Veith FJ. Diagnosis and treatment of chronic lower extremity ischemia. Vasc Med 1998; 3: 291-9.
11 Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.